Development and validation of a polycystic liver disease complaint-specific assessment (POLCA)

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 1143-1150

  Temmerman, Frederik ^a   Dobbels, Fabienne ^a   Ho, Thien Anh ^b   Pirson, Yves ^b   Vanslembrouck, Ragna ^a   Coudyzer, Walter ^a   Bammens, Bert ^a   Van Pelt, Jos ^a   Pirenne, Jacques ^a   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Health related quality of life; Hepatomegaly; Liver transplantation; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; CYCLOPEPTIDE; SOMATOSTATIN;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; CONVERGENT VALIDITY; CRITERION RELATED VALIDITY; DISEASE SEVERITY; FEMALE; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYCYSTIC LIVER DISEASE COMPLAINT SPECIFIC ASSESSMENT; PRIORITY JOURNAL; SELF REPORT; SHORT FORM 36; VALIDATION STUDY; AGED; ANALOGS AND DERIVATIVES; CYSTS; HEALTH SURVEY; HEPATOMEGALY; LIVER DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; CYSTS; FEMALE; HEALTH SURVEYS; HEPATOMEGALY; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SELF REPORT; SEVERITY OF ILLNESS INDEX; SOMATOSTATIN;

EID: 84932109155     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.06.024     Document Type: Article

References (36)

1. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, et al. Polycystic liver: Clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008;28: 264-270.
2. Van Keimpema L, De Koning DB, Van Hoek B, Van Den Berg AP, Van Oijen MG, De Man RA, et al. Patients with isolated polycystic liver disease referred to liver centres: Clinical characterization of 137 cases. Liver Int 2011;31: 92-98.
3. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, et al. Systematic review: The pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011;34: 702-713.
4. Schnelldorfer T, Torres VE, Zakaria S, Rosen CB, Nagorney DM. Polycystic liver disease: A critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009;250: 112-118.
5. Pirenne J, Aerts R, Yoong K, Gunson B, Koshiba T, Fourneau I, et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001;7: 238-245.
6. van Keimpema L, Nevens F, Adam R, et al. Excellent survival after liver transplantation for isolated polycystic liver disease: An European Liver Transplant Registry study. Transpl Int 2011;24: 1239-1245.
7. van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, et al. Lanreotide reduces the volume of polycystic liver: A randomized, doubleblind, placebo-controlled trial. Gastroenterology 2009;137: 1661-1668.
8. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-Acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21: 1052-1061.
9. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, et al. The long-Term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012;35: 266-274.
10. Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, et al. Young women with polycystic liver disease respond best to somatostatin analogues: A pooled analysis of individual patient data. Gastroenterology 2013;145: 357-365.
11. Temmerman F, Gevers T, Ho TA, Vanslembrouck R, Coudyzer W, van Pelt J, et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: Pooled analysis of individual patient data. Aliment Pharmacol Ther 2013;38: 397-406.
12. Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial. J Hepatol 2013;59: 153-159.
13. US Department of Health and Human Services Food and Drug Administration. Guidance for industry. Patient reported outcome measures: Tools in medical product development to support labeling claims, www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.
14. Kimberlin CL, Winterstein AG. Validity and reliability of measurement instrument used in research. Am J Health Syst Pharm 2008;65: 2276-2284.
15. Leventhal H, Johnson JE. Laboratory and field experimentation: Development of a theory of self-regulation. In: Wooldridge PJ, editor. Behavioral science and nursing theory. St. Louis, MO: Mosby; 1983. p. 189-262.
16. Rhodes VA, Watson PM. Symptom distress-The concept: Past and present. Semin Oncol Nurs 1987;3: 242-247.
17. Russell RT, Pinson CW. Surgical management of polycystic liver disease. World J Gastroenterol 2007;13: 5052-5059.
18. Lang H, von Woellwarth J, Oldhafer KJ, Behrend M, Schlitt HJ, Nashan B, et al. Liver transplantation in patients with polycystic liver disease. Transpl Proc 1997;29: 2832-2833.
19. Swenson K, Seu P, Kinkhabwala M, Maggard M, Martin P, Goss J, et al. Liver transplantation for adult polycystic liver disease. Hepatology 1998;28: 412-415.
20. Koyama I, Fuchinoue S, Urashima Y, Kato Y, Tsuji K, Kawase T, et al. Living related liver transplantation for polycystic liver disease. Transpl Int 2002;15: 578-580.
21. Lerut J, Ciccarelli O, Rutgers M, Orlando G, Mathijs J, Danse E, et al. Liver transplantation with preservation of the inferior vena cava in case of symptomatic adult polycystic. Transpl Int 2005;18: 513-518.
22. Ueno T, Barri YM, Netto GJ, Martin A, Onaca N, Sanchez EQ, et al. Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome. Transplantation 2006;82: 501-507.
23. Kirchner GI, Rifai K, Cantz T, Nashan B, Terkamp C, Becker T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006;12: 1268-1277.
24. Dan AA, Younossi ZM. Quality of life and liver transplantation in patients with polycystic liver disease. Liver Transpl 2006;12: 1184-1185.
25. Mekeel KL, Moss AA, Reddy KS, et al. Living donor liver transplantation in polycystic liver disease. Liver Transpl 2008;14: 680-683.
26. Van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut 2008;57: 1338-1339.
27. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al. Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010;5: 783-789.
28. Khadka J, Gothwal VK, McAlinden C, Lamoureux EL, Pesudovs K. The importance of rating scales in measuring patient-reported outcomes. Health Qual Life Outcomes 2012;10: 1477-7525.
29. Gigot JF, Jadoul P, Que F, Van Beers BE, Etienne J, Horsmans Y, et al. Adult polycystic liver disease: Is fenestration the most adequate operation for long-Term management? Ann Surg 1997;225: 286-294.
30. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003;37: 164-171.
31. Ware Jr. JE. SF-36 health survey update. Spine 2000;11: 3130-3139.
32. Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 health survey. Lincoln, RI: QualityMetric Incorporated; 2000.
33. Urata K, Kawasaki S, Matsunami H, Hashikura Y, Ikegami T, Ishizone S, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology 1995;21: 1317.
34. Yilmaz TU, Sözen H, Kiliç K, Erbas G, Dalgiç A. Fenestration treatment for polycystic liver disease improved quality of life. Am Surg 2013;79: E116-E118.
35. Arrazola L, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transpl 2006;12: S110-S111.
36. Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10: 166-173.